|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (ABCL, NASDAQ) |
Company Size: |
100-499 Employees In BC (100-499 Total)
100-499 In BC (100-499 Total)
|
Year Founded: |
2012 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
AbCellera, drug discovery platform, antibodies, genomics, antibody therapeutics
|
Profile Views: |
11,432 Company Profile Views |
|
|
|
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science.
We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development |
|
|
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6 Million CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105 Million USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483 Million USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6M CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105M USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483M USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
|
|
|
|
|
Jan 23, 2023
|
AbCellera Announces U.S. Patent Trial and Appeal Board Upholds its Microfluidic Cell Culture Patent
|
|
Dec 19, 2022
|
AbCellera and AbbVie Partner to Advance New Antibody Therapies
|
|
Dec 2, 2022
|
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
|
|
Nov 24, 2022
|
AbCellera Reports Q3 2022 Business Results, Q3 Revenue Rises Sharply YoY to US $101 Million
|
|
Nov 18, 2022
|
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform
|
|
Sep 22, 2022
|
AbCellera Announces More Details on the Second Phase of its Global Headquarters Expansion in Vancouver (3 Facilities)
|
|
Sep 15, 2022
|
AbCellera Breaks Ground on Phase II of Their New 380,000 Sq Ft State-of-the-Art Tech Campus in Vancouver
|
|
Aug 10, 2022
|
AbCellera Reports Q2 2022 Business Results, Company Maintains Strong $1.02 Billion Liquid Cash Cushion
|
|
Aug 5, 2022
|
AbCellera Announces Multi-Target Partnership with Atlas Venture to Discover Therapeutic Antibodies for Stealth-Stage Company
|
|
Jul 29, 2022
|
AbCellera Signs Multi-Year Collaboration Deal with Versant Ventures to Accelerate Drug Development for its Portfolio of Biotech Companies
|
|
|
1 - 10 of 89 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
